Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
Overview
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。 ⑵用于治疗局部晚期或转移性尿路上皮癌。 ⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。 ⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。 ⑸用于治疗晚期恶性实体瘤
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
TEVIMBRA
Manufacturer:BeOne Medicines USA, Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2024/03/16
NDC:72579-121
Singapore Approved Products
TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML
Manufacturer:Boehringer Ingelheim Biopharmaceuticals (China) Ltd
Form:INFUSION, SOLUTION CONCENTRATE
Strength:100mg/10mL
Online:Yes
Approved: 2024/09/19
Approval:SIN17089P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath